HIPRA launches ERAVAC, the new vaccine for RHDV2, in Italy

Filtered by {{cFt}} Back to news
Home News HIPRA launches ERAVAC, the new vaccine for RHDV2, in Italy

HIPRA launches ERAVAC, the new vaccine for RHDV2, in Italy

On 11, 12 and 13 October, HIPRA brought together the main veterinarians in the rabbit industry in the cities of Verona, Padua and Fossano (Italy).

Enrico Bailo (HIPRA Italia Business Manager) opened the event with a presentation on HIPRA and its involvement and experience in the production of vaccines for the rabbit industry. Maria Padrell (Product Manager, Rabbits Business Unit) presented an update on the epidemiological status of the Rabbit Haemorrhagic Disease Virus Type 2 (RHDV2), providing recent data on the presence and spread of the virus in Europe, as well as the monitoring carried out in DIAGNOS Service.

She then presented ERAVAC®, the new HIPRA vaccine for RHDV2 registered throughout the European Union. The vaccine contains an oil adjuvant that enables the appropriate formation of antibodies (humoural immunity) from 30 days of age, and its safety has been tested with the absence of adverse reactions. Finally, Xavier Mora, a veterinarian with expertise in rabbit keeping, concluded the event with a presentation on practical cases and field experiences with the RHDV2 virus and vaccine.

HIPRA consolidated its commitment to RHDV2 prevention and showed its support to the Italian rabbit industry with this event.

Share this on